Fluticasone Propionate

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31F3O5S
Molecular Weight	500.571
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF

InChI

InChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N

InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H31F3O5S
Molecular Weight	500.571
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00588
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluticasone.html

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis. Fluticasone propionate binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: http://www.drugbank.ca/drugs/DB00588	Agonist 2752		1.0 nM [EC50]
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00588	Agonist 2752		0.7 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Corticosteroid-responsive dermatoses 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019957s012lbl.pdf	Primary		Approved 8583	CUTIVATE Approved Use CUTIVATE® Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. Launch Date 1990

C_max

Value	Dose	Co-administered	Analyte	Population
23364 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
14148 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076633_ORIGINAL%20APPROVAL_PACKAGE.pdf	1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
16 mg single, oral Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
2 mg 2 times / day multiple, intranasal Highest studied dose Dose: 2 mg, 2 times / day Route: intranasal Route: multiple Dose: 2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
1320 ug 1 times / day multiple, respiratory Highest studied dose Dose: 1320 ug, 1 times / day Route: respiratory Route: multiple Dose: 1320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
3520 ug single, respiratory Highest studied dose Dose: 3520 ug Route: respiratory Route: single Dose: 3520 ug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
25 ug 2 times / day steady, respiratory Dose: 25 ug, 2 times / day Route: respiratory Route: steady Dose: 25 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	Other AEs: Pneumonia mycoplasmal... Other AEs: Pneumonia mycoplasmal (serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02980133
50 ug 2 times / day steady, respiratory Dose: 50 ug, 2 times / day Route: respiratory Route: steady Dose: 50 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	Other AEs: Disruptive mood dysregulation disorder... Other AEs: Disruptive mood dysregulation disorder (serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02980133
200 ug 1 times / day steady, intranasal Dose: 200 ug, 1 times / day Route: intranasal Route: steady Dose: 200 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01817790	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT01817790	Other AEs: Thirst, Gastrointestinal viral infection... Other AEs: Thirst (below serious, 1 patient) Gastrointestinal viral infection (below serious, 1 patient) Headache (below serious, 2 patients) Throat irritation (below serious, 1 patient) Palpitations (below serious, 1 patient) Laceration (below serious, 1 patient) Hypertension (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01817790
880 ug 2 times / day steady, oral Dose: 880 ug, 2 times / day Route: oral Route: steady Dose: 880 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00275561	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00275561	Other AEs: Esophageal candidiasis... Other AEs: Esophageal candidiasis (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00275561
880 ug 2 times / day steady, oral Dose: 880 ug, 2 times / day Route: oral Route: steady Dose: 880 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00426283	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00426283	Other AEs: General system disorders NEC, General system disorders NEC... Other AEs: General system disorders NEC (below serious, 7 patients) General system disorders NEC (below serious, 2 patients) General system disorders NEC (below serious, 1 patient) General system disorders NEC (below serious, 5 patients) General system disorders NEC (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00426283

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A5 136	CYP1A1 389 CYP1A2 1197 CYP1B1 104 CYP2A6 626 CYP2B6 776 CYP2C8 810 CYP2C18 149 CYP2C19 1119 CYP2E1 729 CYP3A5 446 CYP3A7 109 P-gp 2052	P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubs.acs.org/doi/abs/10.1021/tx100124k Page: -	weak
CYP3A5 201	inhibitor 4027 Sources: https://pubs.acs.org/doi/abs/10.1021/tx100124k Page: -	yes
P-gp 1932	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X12001019 Page: -	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 389	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP1B1 104	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C18 149	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
P-gp 2052	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X12001019 Page: -	weak
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	yes [Km 3.8 uM]
CYP3A7 109	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	yes [Km 5.2 uM]
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209022Orig1s000ClinPharmR_rev.pdf#page=14 Page: 14.0	yes [Km 5.3 uM]	yes (co-administration study) Comment: Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209022Orig1s000ClinPharmR_rev.pdf#page=14 Page: 14.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31441	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31441
ChemicalBook	CB1252206	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1252206
ChemicalBook	CB52622685	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52622685
ChemicalBook	CB5274961	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5274961
ChemicalBook	CB94798094	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB94798094
eMolecules	2736271	https://www.emolecules.com/cgi-bin/more?vid=2736271
eMolecules	31226118	https://www.emolecules.com/cgi-bin/more?vid=31226118
MolPort	MolPort-003-847-468	https://www.molport.com/shop/molecule-link/MolPort-003-847-468
Selleck Chemicals	fluticasone-propionate-Flonase-Veramyst	http://www.selleckchem.com/products/fluticasone-propionate-Flonase-Veramyst.html
ZINC	ZINC000003920027	http://zinc15.docking.org/substances/ZINC000003920027

PubMed

Title	Date	PubMed
Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy.	2000 Nov	11101185
Small airway inflammation in asthma.	2001	11737932
Inhaled fluticasone propionate for chronic asthma.	2001	11687040
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?	2001	11577791
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?	2001	11520256
Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs.	2001	11520251
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.	2001	11511026
Topical corticosteroids in nasal polyposis.	2001	11368283
Improvement in health care utilization and pulmonary function with fluticasone propionate in patients with steroid-dependent asthma at a National Asthma Referral Center.	2001 Aug	11515977
Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study.	2001 Aug	11477728
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.	2001 Aug 15	11530030
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.	2001 Aug 4	11485952
Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.	2001 Dec	11742910
One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height.	2001 Dec 1	11739137
The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.	2001 Dec 1	11739135
Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo.	2001 Feb	11259988
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.	2001 Feb	11174215
Recruitment of CD1a+ Langerhans cells to the nasal mucosa in seasonal allergic rhinitis and effects of topical corticosteroid therapy.	2001 Feb	11167372
The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3 and GM-CSF mRNA and protein.	2001 Jan	11167953
Retrospective study on fluticasone propionate aqueous nasal spray efficacy in patients with allergic rhinitis: evaluation of clinical and laboratory parameters.	2001 Jan	11167349
Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.	2001 Jan-Feb	11294367
Fluticasone propionate: a rare contact sensitizer.	2001 Jan-Feb	11174134
Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression.	2001 Jul	11510784
Drugs for the treatment of allergic diseases.	2001 Jul	11488426
Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.	2001 Jul	11485708
Pharmacokinetics of intranasal corticosteroids.	2001 Jul	11449203
A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.	2001 Jun	11559968
[Peak inspiratory flow rates attained by asthmatic patients through a dry-powder inhaler of fluticasone propionate].	2001 Jun	11517519
Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray.	2001 Jun	11486442
Safety of inhaled corticosteroid therapy in young children with asthma.	2001 Jun	11428737
Presence of fluticasone propionate on human nasal mucosal surface and in human nasal tissue over a period of 24 h after intranasal application.	2001 Jun	11421898
Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system.	2001 Jun 19	11397578
Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.	2001 Jun 8	11549975
Onset of therapeutic effect of fluticasone propionate aqueous nasal spray.	2001 Mar	11289326
A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma.	2001 May	11392363
Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.	2001 Nov	11730179
Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation.	2001 Nov 1	11673549
Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis.	2001 Nov 23	11730731
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.	2001 Oct	11686419
Fluticasone propionate aqueous nasal spray in pregnancy rhinitis.	2001 Oct	11678947
Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression in asthmatic children treated with inhaled steroids.	2001 Oct	11600561
Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate.	2001 Sep	11555383
The penetration of 0.005% fluticasone propionate ointment in eyelid skin.	2001 Sep	11511836
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.	2001 Sep 1	11549529
Intracranial hypertension and nasal fluticasone propionate.	2001 Sep 22	11566840
Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry.	2001 Sep 25	11587347
Aerosol characterization of nebulized intranasal glucocorticoid formulations.	2001 Summer	11681655

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Dermatitis Cream/Ointment: Apply a thin film to affected area twice a day

Route of Administration: Topical

In Vitro Use Guide

Pretreatment with Fluticasone propionate (10(-11) M to about 10(-7) M, 24 h) inhibited TNF-alpha-induced VCAM-1 mRNA expression in BEAS-2B in a dose-dependent manner

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:50:59 GMT 2025` Edited by `admin` on `Mon Mar 31 17:50:59 GMT 2025`
Record UNII	O2GMZ0LF5W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Fluticasone Propionate

Official Name

English

ADVAIR HFA COMPONENT FLUTICASONE PROPIONATE

Preferred Name

English

FLUTICASONE PROPIONATE [ORANGE BOOK]

Common Name

English

ADVAIR COMPONENT FLUTICASONE PROPIONATE

Brand Name

English

FLUTICASONE PROPIONATE [USP MONOGRAPH]

Common Name

English

CUTIVATE

Brand Name

English

S-FLUOROMETHYL 6.ALPHA., 9.ALPHA.-DIFLUORO-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-17.ALPHA.-PROPIONYLOXYANDROSTA-1,4-DIENE-17.BETA-. CARBOTHIOATE

Common Name

English

FLIXOTIDE

Brand Name

English

FLUTICASONE PROPIONATE [EP MONOGRAPH]

Common Name

English

ARMONAIR RESPICLICK

Brand Name

English

LIPO-102 COMPONENT FLUTICASONE PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [JAN]

Common Name

English

FLOVENT

Code

English

CCI18781

Code

English

FLUTICASONE PROPIONATE [USP-RS]

Common Name

English

PF-00241939

Code

English

FLUTICASONE PROPIONATE [MART.]

Common Name

English

AIRDUO RESPICLICK COMPONENT FLUTICASONE PROPIONATE

Brand Name

English

NSC-759889

Code

English

DYMISTA COMPONENT FLUTICASONE PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [USAN]

Common Name

English

CCI-18781

Code

English

XHANCE

Brand Name

English

Fluticasone propionate [WHO-DD]

Common Name

English

ANDROSTA-1,4-DIENE-17-CARBOTHIOIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(1-OXOPROPOXY)-, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-S-(FLUOROMETHYL) ESTER

Common Name

English

FLUTICASONE PROPIONATE [MI]

Common Name

English

FLUTICASONE-17-PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [VANDF]

Common Name

English

FLONASE

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

273208